first indo-us bilateral meet on molecular imaging
DESCRIPTION
The first Indo-US Bilateral Meet on Molecular Imaging. Organizers:Gopal Pande, CCMB, India,Rao Papineni, Carestream Health Inc, USATRANSCRIPT
Indo-US Science and Technology ForumIUSSTF
Indo-US Workshop on
Applications of Molecular Imaging in Health, Disease and Drug Discovery
Nov 8-10, 2010
Centre for Cellular & Molecular BiologyHyderabad - 500 007, India
CCMB
arestream
Co-organized by
Indo-US Workshop on “Applications of Molecular Imaging in Health, Disease and Drug Discovery” 1
Imaging of molecules, cells, tissues, organs and whole organisms has been en vogue ever since the first X-ray images of Albert von Kolliker's ring bearing hand were taken by Wilhelm Conrad Roentgen in 1896. Over the past century significant advancement has occurred in this field, that has increased the sensitivity and specificity of biomedical imaging and completely changed the way radiological medicine is practiced. The first decade of the new millennium has brought even more impetus to the field thus beginning a new era for the application of “imageology” in a large spectrum of disciplines that includes interactions between small molecules, understanding higher order brain functions and discovery of new drugs.
The labs in United States have been pioneers in this newly developing science and the National Institutes of Health has started a new institute specifically targeted for research on biomedical imaging, whose Deputy Director is attending the workshop. Indian labs are also becoming aware of the power of these developments and new infrastructure is being established at several institutes where bioimaging will be practiced extensively. The Indo-US Science and Technology Forum, New Delhi recognized this synergy between the US and Indian labs and approved a proposal submitted by CCMB, Hyderabad, India and Carestream Health Inc. Woodbridge, USA to hold this workshop. On behalf of our respective institutions we are privileged to host a very knowledgeable faculty for the workshop and we warmly welcome all the participants to CCMB Hyderabad. We are thankful to the Director of CCMB who has graciously extended the use of all the facilities at CCMB for this workshop.
Hope all of you will have fun and learn new things in the two and a half days that you spend here!
Gopal Pande Rao PapineniCCMB Carestream Health Inc.
A Note from the Organizersto
ALL PARTICIPANTS AND SPEAKERS OF THE INDO-US WORKSHOP ON “APPLICATIONS OF MOLECUALR IMAGING IN HEALTH,
DISEASE AND DRUG DISCOVERY” NOVEMEBER, 8-10, 2010
atCCMB, HYDERABAD, INDIA
Indo-US Science and Technology ForumIUSSTF
Venue: CCMB Lecture Hall
AGENDA
Indo-US Workshop onApplications of Molecular Imaging in Health, Disease and Drug Discovery
November 8-10, 2010
Indo-US Workshop on “Applications of Molecular Imaging in Health, Disease and Drug Discovery” 2
Indo-US Science and Technology ForumIUSSTF
6.00 pm - Arrival and Mixer – CCMB Centre Court
thMonday, the 8 November, 2010
8.45 am - Opening Remarks by
Ch. Mohan Rao, Director, CCMB, Belinda Seto, Dy. Director, NIBIB and Nishritha Bopana, Science Officer, IUSSTF
Session I : Chairperson – Kakarla Subbarao9:15 to 11:00 am
Molecular Medicine: Present and Future Belinda SetoNIBBB, Bethesda
Potential of MRI and In-vivo MR Spectroscopy in Disease Process N.R. JagannathanAIIMS, New Delhi
11.00 - 11.15 am - Tea/Coffee Break
Session II : Chairperson – Arun K. Gupta11.15 - 1.00 pm
Pre-Clinical Molecular Imaging Applications in Cancer Research Rheal TownerAMRC, Oklahoma City
Use of optical spectroscopic and imaging techniques for biomedical diagnosis P.K. GuptaCAT, Indore
1.00 - 2.00 pm - Lunch Break
Session III : Chairperson – Kit Lam02.00 - 03.40 pm
Image guided interventions A. K. Gupta SCTIMS, Thiruvananthapuram
Combined Anatomical and Molecular Imaging with Therapeutics using Shanthi K. Nair Biocompatible Nanoparticles AIMSRC, Kochi
03.40 - 4.00 pm - Tea Break4.00 pm - Departure to Golkonda Fort
8.00 pm - Dinner at Taramati
thSunday, the 7 November, 2010
Indo-US Workshop on “Applications of Molecular Imaging in Health, Disease and Drug Discovery” 3
Indo-US Science and Technology ForumIUSSTF
thTuesday, the 9 November, 2010
Plenary Session IV : Chairperson – Belinda Seto9.00 – 11.00 am
From combinatorial chemistry to nanoparticles to Kit Lamcancer imaging and therapy UCDCC, Davis
Imaging RNA in cells and in animals Samit AdhyaIICB, Kolkata
11.00 - 11.15 am - Tea/Coffee Break
Session V : Chairperson – Arvind K. Chaturvedi11.15 - 1.00 pm
Nano "Solutions" for Therenostics Mark KesterPenn State Univ., Hershey
Fluorescence based imaging of tumor cells Gopal KunduNCCS, Pune
1.00 - 2.00 pm - Lunch Break
Session VI : Chairperson – B. Ravindran02.00 - 03.40 pm
In vivo cellular imaging and its role in cell therapy Ali ArbabCMIL, HFH, Detroit
CNMR Investigations of Excitatory and Inhibitory Anant PatelNeurotransmission in Cerebral Disorders CCMB, Hyderabad
03.40 - 4.00 pm - Tea Break
Session VII : Chairperson - Samit Adhya4.00 - 04.50 pm
Role of Molecular Imaging in Drug Discovery Mathew ThakurTJUH, Philadelphia
04.50 – 06.00 pm - POSTER DISCUSSION06.00 – 07.00 pm Visit to CRF
07.00 – 9.00 pm - Cultural Program and Dinner (CCMB Terrace)
Indo-US Workshop on “Applications of Molecular Imaging in Health, Disease and Drug Discovery” 4
Indo-US Science and Technology ForumIUSSTF
thWednesday, 10 November, 2010
9.30 - 11.30 am - Panel Discussion
11.30 – 12.00 Noon - Wrap up
12.00 Noon - Lunch & Disperse
Kakarla Subbarao Jyostna Rao
John DelliSanti Surender Reddy
Neeraj GuptaB.S. Dwarakanath
Indo-US Workshop on “Applications of Molecular Imaging in Health, Disease and Drug Discovery”
Organizers
Dr. Gopal PandeScientist, Centre for Cellular & Molecular BiologyUppal Road, Habsiguda, Hyderabad 500 007
Email: [email protected]
Direct Tel: +91-40-27192605, Fax: +91-40-27160311
Dr. Rao Papineni Senior Principal Investigator , Res. & Development
Carestream Health Inc, USA 4, Research Drive, WoodBridge, CT 06525
Email: [email protected] Tel 203-676-1163 (USA): +91-9177532584 (India)
LIST OF PARTICIPANTS
SPEAKERS
INVITEES
S. No.
S. No.
Name of the Speaker
Name of the Speaker
Institute & Address
Institute & Address
City
City
From USA
1
1
Dr. Rheal Towner
Dr. Ch. Mohan Rao
Director of Advanced Magnetic Resonance Center, 825,
thNortheast, 13 Street
Director, Centre for Cellular & Molecular Biology
Oklahoma City
Hyderabad
omrf.org
2
2
Dr. Mathew Thakur Thomas Jefferson University Hospital
CEO, Carestream Health Inc
Philadelphia mjefferson.edu
3
3
4
5
Dr. Mark Kester Distinguished Professor, Penn State University
Science Officer, Indo-US Science and Technology Forum
Hershey, PA
New Delhi
mpsu.edu
indousstf.org
Dr. Ali Arbab Associate Scientist and Director, Cellular & Molecular Imaging Laboratory, Henry Ford Hospital
Detroit shfh.edu
Dr. Kit Lam Chair, Dept. of Biochemistry and Molecular Medicine, UC Davis Cancer Centre
Davis, CA Kucdavis.edu
6 Dr. Belinda SetoDeputy Director, National Institute of Biomedical Imaging and Bioengineering
Bethesda
Indo-US Workshop on “Applications of Molecular Imaging in
Health, Disease and Drug DiscoveryCentre for Cellular & Molecular Biology, Hyderabad, India
Nov 8-10, 2010
5
ccmb.res.in
Dr. John DelliSanti WoodBridgecarestreamhealth.com
Dr. Nishritha Bopana
Indo-US Science and Technology ForumIUSSTF
Indo-US Workshop on “Applications of Molecular Imaging in Health, Disease and Drug Discovery”
Indo-US Science and Technology ForumIUSSTF
6
From India
7 Dr. Gopal Kundu Scientist, National Centre for Cell Science
Pune kunducom
8
9
10
11
12
13
14
15
16
Dr. P.K. GuptaHead, Laser Biomedical Applications & Instrumentation Division, CAT
Indore pkgupta
Scientist, Centre for Cellular & Molecular Biology Hyderabad abpateln
Dr. Anant Patel
Dr. R.N. Jagannathan Prof. & Head, MRI Facility, All India Institute of Medical Sciences
New Delhi
jagancom,jagancom,
nrjgj@in
Scientist, Indian Institute of Chemical Biology
Kolkata samit.res.in Dr. Samit Adhya
Dean, Amrita Institute of Medical Sciences and Research Centre, Amrita Lane AIMS Ponekkara Post
shantinair@edunaircom
Dr. Shanti K. Nair Kochi
Dr. Kakarla Subbarao
Dr. Arvind K. Chaturvedi
Dr. B Ravindran
Dr. Arun K Gupta
Ex-Director, NIMS,KREST Building, Sheikpet, Hyderabad. Tel: 23560005
Prof. & Head, Department of Radiology and Imaging, Rajiv Gandhi Cancer Institute & Research Center
Director, Institute of Life Sciences
Professor and HeadDepartment of Imaging Sciencesand Interventional Radiology, Sree Chitra Tirunal Inst. for Medical Sciences & Technology
Hyderabad
New Delhi
Bhubaneswar
Trivandrum
kakarlasubbaraocom
arvindatcom
balaraviinravindrancom
gupta@ingupta@[email protected]
1
2
3
4
5
6
PANEL DISCUSSION
Dr. Jyotsna Rao Apollo Gleneagles PET CT Centre Hyderabad jyotsnaelcom
Dr. Kakarla Subbarao Ex-Director, NIMS, Hyderabad kakarlasubbaraocom
[email protected]. John DelliSanti CEO, Carestream Health Inc.
CEO, Vijaya Dignostics
WoodBridge
Dr. Surender Reddy Hyderabad
Mr. Neeraj Gupta
Dr. B.S. Dwarakanath
ncom
bo in
Imperial Life Sciences
INMAS Delhi
Indo-US Workshop on “Applications of Molecular Imaging in Health, Disease and Drug Discovery”
Indo-US Science and Technology ForumIUSSTF
7
Gurgaon
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
Dr. Sujata Mohanty
Dr. Marshal
Dr. Shashi Singh
Dr. N. Madhusudhana Rao
Dr. Lekha Dinesh Kumar
Mr. G. Srinivas
All India Institute of Medical Sciences
Scientist, Centre for Cellular &Molecular Biology
Scientist, Centre for Cellular & Molecular Biology
Scientist, Centre for Cellular & Molecular Biology
Scientist, Centre for Cellular & Molecular Biology
Technical Officer, Centre for Cellular &Molecular Biology
New Delhi
Hyderabad
Hyderabad
Hyderabad
Hyderabad
Hyderabad
sujmohantyin
marshal.in
shashisin
madhuin
lekhan
gsri.in
Mr. T. AvinashrajSTA , Centre for Cellular & Molecular Biology Hyderabad taraj.in
Dr. Anil Misra Delhi akmishra.in
Indo-US Workshop on “Applications of Molecular Imaging in Health, Disease and Drug Discovery”
Indo-US Science and Technology ForumIUSSTF
8
Dr. M. Ramanadham
Dr. B.S. Dwarakanath
Dr. E.J.J. Samuel
School of Life Sciences, University of Hyderabad Hyderabad mrnsl@in
Scientist, Head, Division of Radiation Biosciences, Institute of Nuclear Medicine & Allied Sciences
Scientist, Institute of Nuclear Medicine & Allied Sciences
Delhibsd.org
bsd@iin
Sr. Professor of Physics, Photonics Division, VIT University
Vellore jebamonica.in
Dr. N. Harishankar
Mr. Sachindra
Parashar
Scientist, National Institute of Nutrition Hyderabad hsnemanicom
National Centre for Cell Science Pune sachindrabiotech@
Dr. Lakshmi Chelluri Global Hospitals Hyderabad apparusucom
Dr. Aleem Ahmed Khan
Scientist, Deccan Medical College of Sciences
Hyderabad aleemrediffmail.com
PARTICIPANTS
18
19
GurgaonMr. Jai Raj Imperial Life Sciences jairajom
Ms. Supriya Saraswati National Centre for Cell Science Pune
Indo-US Workshop on “Applications of Molecular Imaging in Health, Disease and Drug Discovery”
Indo-US Science and Technology ForumIUSSTF
9
16
17
Ms. Sangeeta Chakraborty
MCBL, Indian Institute of Science [email protected]
Dr. Daniela Ahl Imperial Life Sciences Gurgaon daniela..com
POSTER TITLES
1. Specificity in Gene Silencing Using Multifunctional Nanoparticles1 1 2 2Rao V. Papineni , Tao Ji , Thirupandiyur Udayakumar , Mohammed M. Shareef , Mansoor M.
2 2Ahmed , Alan Pollack1Carestream Molecular Imaging, Carestream Health, Inc., New Haven, CT, USA;2Radiation Oncology, University of Miami, Miami, FL, USA.
2. Bisphosphonate targeting to specific skeletal sites in mice with whole body vibrationRao V L Papineni. Sean Orton, Tao ji, Hans Schmitthenner, William McLaughlin, Douglas Vizard and Jingyi PanCarestream Molecular Imaging, Carestream Health Inc., New Haven, CT
3. Roadmap for molecular imaging in emerging economies-A focus on nuclear imagingJyotsna Rao and Rao V. L. Papineni,Apollo Hospitals and Carestream Health Inc.
4. Safety and efficacy of the human fetal liver derived stem cell transplantation as supportive modality in the management of end stage Decompensated liver cirrhosis – A2 year follw up studyHabibullah CM*, Aejaz Habeeb M*, Aleem A. Khan*, Mahaboob V Shaik*, Parveen N*, Rajendraprasad A*, Mohammed A Aleem*, Srinivas G†, Avinash Raj T†, Santosh K Tiwari*, Kumaresan K‡ , Venkateswarlu J*, Gopal Pande†, Linda Powers#*Centre for Liver Research and Diagnostics, Deccan College of Medical Sciences, Kanchanbagh, Hyderabad, Andhra Pradesh, India.†Center for Cellular and Molecular Biology, Uppal Road, Hyderabad ‡KK Scan Centre, Somajiguda, Hyderabad #Vesta Therapeutics, Inc., 801 Capitola Dr., Suite 8, Durham, NC 27713, USA.
5. Techniques to Improve 3D Optical Imaging Quantification and Sensitivity Jai Raj Imperial Life Sciences P. Ltd., Gurgaon
6. Invivo imaging of murine bone marrow and human foetal liver cells in SCID & nude mice1 1 1 2 1T. Avinash Raj , G. Srinivas , J. Mahesh Kumar , Aleem A. Khan , Gopal Pande
1 Center for Cellular and Molecular Biology, Uppal Road, Hyderabad.2 Centre for Liver Research and Diagnostics, Deccan College of Medical Sciences,
Kanchanbagh, Hyderabad.
Indo-US Workshop on “Applications of Molecular Imaging in Health, Disease and Drug Discovery” 10
Indo-US Science and Technology ForumIUSSTF
7. Evaluation of the autologous bone marrow derived mononuclear cell therapy in the infarcted myocardium by imaging analysis – a case report
†Authors: Alla GK Gokhale., Lakshmi Kiran Chelluri., Kumaresan K. , Subramanyam G., Sudhakar K., Satish Vemuri., Tanya Debnath., Ratnakar KS
†Affiliations: Global Hospitals, Lakdi-ka-Pool, Hyderabad., KK Nuclear Clinic, Somajiguda, Hyderabad
Indo-US Workshop on “Applications of Molecular Imaging in Health, Disease and Drug Discovery” 11
Indo-US Science and Technology ForumIUSSTF
ABSTRACTS
Indo-US Workshop on “Applications of Molecular Imaging in Health, Disease and Drug Discovery”
Indo-US Science and Technology ForumIUSSTF
12
Molecular Medicine: Present and Future
Advances in molecular medicine have the potential and promise to transform medicine from the “see
and treat” paradigm to one that emphasizes personalized, predictive and preventive strategies. To
facilitate the transformation, the U.S. National Institutes of Health support and conduct research that
capitalizes on genomic and proteomic data as a basis for developing diagnostic technologies and
targeted therapy at the cellular and molecular levels. As an example, I plan to discuss a research
project that aims to identify circulating cells and molecular markers in blood samples that will
characterize subsets of patients for targeted therapies. The technology involves microfluidic chips
designed with high throughput capability to screen multiple patient blood samples to capture
signature cells with subsequent identification of the disease genomic, proteomic or molecular
signatures. The platform can be developed to integrate these tests such that a comprehensive picture
of the patient's condition is available to the physician. Immediate applications are envisioned in
cancer and potentially atheromatous disease (the two leading causes of death).
The comprehensive platform technologies may transform medicine by: targeting therapies specific
for patients; predicting responsiveness to therapy; monitoring disease progression and treatment
response at the cell/molecular level to expedite consideration of alternative therapies and probing
the fundamental biology of disease resolution or progression. This should lead to more precise
diagnoses, personalized treatment for patient sub-groups, improved outcomes and reduced cost due
to preventing advanced stages of disease.
Belinda Seto, Ph.D.Deputy Director, National Institute of Biomedical Imaging and Bioengineering
Bethesda, USA
Role of in vivo Magnetic Resonance Spectroscopic Imaging (MRSI)
and Diffusion MRI (DWI) in the Evaluation of Prostate Cancer
N. R. Jagannathan
Department of NMR and MRI Facility All India Institute of Medical Sciences
New Delhi – 110029, India.
Indo-US Workshop on “Applications of Molecular Imaging in Health, Disease and Drug Discovery”
Indo-US Science and Technology ForumIUSSTF
13
Prostate cancer is the most common male cancer in the West and second most common cause of
cancer related deaths. The incidence of prostate cancer in India is however lower but a steady increase
has been observed in recent years especially in urban areas like Delhi and Mumbai. The key to
treatment is the detection of malignancy at an early stage and monitoring the tumor response to
therapy. The challenges in detection, localization and staging of prostate cancer of existing methods
have prompted us to take the investigation of the role of various MR methodologies in a large cohort
of Indian men prior to biopsy.
The identification of suspicious areas of malignancy are normally carried out using magnetic
resonance imaging (MRI), magnetic resonance spectroscopic imaging (MRSI) and diffusion weighted
imaging (DWI). Till now nearly 250 men were studied using these MR methods in our Institute. Our
data showed that the apparent diffusion coefficient may be a reliable marker to differentiate normal,
benign and malignant prostate tissues similar to the metabolite ratio obtained from MRS. Further; our
results demonstrated that the combined use of MRSI and DWI improved the diagnosis of prostate
cancer.
1The role of 3D H MRSI in directing TRUS guided biopsy of prostate was also evaluated in a large cohort
of patients. The z – and x – coordinates of the voxels suspicious of malignancy from MRSI were used to
direct TRUS guided needle biopsy. The site of biopsy was confirmed by post biopsy MRI and MRSI. MRI
showed the site of biopsy as hypo-intense area on gradient T2 weighted image (T2*) while the MR
spectrum showed reduced citrate and increased choline.
In this talk, our experience on the use of MRSI and DWI methods in the diagnosis of prostate cancer in
Indian men especially in clinically challenging cases of patients with PSA level in the range of 4 – 20
ng/mL and/or abnormal DRE will be presented.
Indo-US Workshop on “Applications of Molecular Imaging in Health, Disease and Drug Discovery” 14
Indo-US Science and Technology ForumIUSSTF
Magnetic resonance imaging (MRI) and spectroscopy (MRS) play important roles as
diagnostic tools for many cancers, including assessments on tumor growth, angiogenesis,
bio-physical parameters, such as diffusion and perfusion, and response to therapy.
Molecular MRI (mMRI) has made some important contributions in the study of angiogenic,
inflammation and apoptotic markers in cancer. A brief discussion on advances in the
development of mMRI contrast agents will be presented. Examples on the use of high
resolution MRI and MRS at 7.0 Tesla to obtain molecular imaging information on
angiogenesis, inflammation and tumor metabolism in rodent pre-clinical models for gliomas
and hepatocellular carcinomas (HCC) will be presented. The concept of mMRI involves the
coupling of an affinity molecule that recognizes a specific target marker (e.g. vascular
endothelium growth factor receptor 2 (VEGF-R2), c-Met, or inducible nitric oxide synthase
(iNOS)) and MRI contrast signaling agents such as gadolinium-ligand- or iron oxide
nanoparticle (IONP)-based constructs. Chemical shift imaging (CSI) as a method to assess
lipid metabolism in tumor models will also be presented. MR methods offer the unique
opportunity to be used as tools to obtain non-invasive in vivo morphological/anatomical,
vascular, metabolic, functional and molecular information in rodent pre-clinical models in
cancer.
1 1 1 1 1 1Rheal A. Towner , Nataliya Smith , Ting He , Sabrina Doblas , Philippe Garteiser , Debra Saunders , 2 2Robert Silasi-Mansat and Florea Lupu
1 2Advanced Magnetic Resonance Center, and Cardiovascular Biology,Oklahoma Medical Research Foundation
th825 N.E. 13 St., Oklahoma City, OK 73104 U.S.A.Phone: (405) 271-7383
FAX: (405) 271-7254Email: [email protected]
Pre-Clinical Molecular Imaging Applications in Cancer Research
Indo-US Science and Technology ForumIUSSTF
P.K. GuptaCAT, Indore Laser Biomedical Applications and Instrumentation Division,
Raja Ramanna Centre for Advanced Technology,
Indore – 452013, India.
E-mail: [email protected]
Use Of Optical Spectroscopic And Imaging Techniquesfor Biomedical Diagnosis
I shall provide an overview of the studies carried out at Laser Biomedical Applications and
Instrumentation Division, RRCAT on the development and utilization of optical techniques for
biomedical imaging and diagnosis. First I shall discuss some representative biomedical imaging
studies carried out using the optical coherence tomography set ups developed at RRCAT. Work
carried out at RRCAT on the use of optical spectroscopy for biomedical diagnosis will be discussed
next and the results of our recent study on a comparative evaluation of the performance of laser
induced fluorescence spectroscopy and Raman spectroscopy for in-vivo diagnosis of the cancer of
oral cavity will be presented. Finally I shall also describe some aspects of the Raman spectroscopic
studies carried out by us on single, optically trapped Red Blood Cells obtained from blood samples
from healthy volunteers and from patients suffering from malaria.
Indo-US Workshop on “Applications of Molecular Imaging in Health, Disease and Drug Discovery” 15
Indo-US Science and Technology ForumIUSSTF
Indo-US Workshop on “Applications of Molecular Imaging in Health, Disease and Drug Discovery” 16
Image guided Interventions
A.K. Gupta
Abstract not received
Professor and HeadDepartment of Imaging Sciences
and Interventional Radiology, Sree Chitra Tirunal Inst. for Medical Sciences & Technology
Thiruvananthapuram
The authors discuss new methodologies and treatments of cancer using molecular imaging and
targeted therapeutics using non-toxic nanoparticles. At the Amrita Centre for Nanosciences a range
of multifunctional nanoparticles have been developed with combined fluorescence, X-Ray and MRI
contrast capability. When such particles can be targeted to cancer cells there is the possibility of early
detection by both anatomical and molecular imaging modalities including the opportunity of
delivering drugs directly to the cells in question. Efforts are currently under way to target cancer stem
cells in addition to cancer cells to enhance early detection and therapeutic efficiencies. The results of
some of our current studies will be presented at this workshop.
Indo-US Workshop on “Applications of Molecular Imaging in Health, Disease and Drug Discovery”
Indo-US Science and Technology ForumIUSSTF
17
Combined Anatomical and Molecular Imaging with Therapeutics using Biocompatible Nanoparticles
Shantikumar Nair and K.ManzoorAmrita Centre for Nanosciences
Amrita Vishwa Vidyapeetham, Kochi
Indo-US Workshop on “Applications of Molecular Imaging in Health, Disease and Drug Discovery”
Indo-US Science and Technology ForumIUSSTF
18
From combinatorial chemistry to nanoparticles to cancer imaging and therapy
1 1 1 1 1 1 1Juntao Luo , Kai Xiao , Yuan-pei Li , Joyce Lee , Nianhuan Yao , Wenwu Xiao , Yan Wang , Michael 2, 3 4 1Kent Holland Cheng , Gangyu Liu , and Kit S. Lam *
1 Department of Biochemistry & Molecular Medicine,Division of Hematology & Oncology, UC Davis 2 3 4Cancer Center, Veterinarian School of Medicine, College of Biological Sciences, Department of
Chemistry, University of California Davis, CaliforniaCorresponding author ([email protected])
Recently we have developed a novel amphiphilic polymer (telodendrimer), comprised of linear
polyethylene glycol, lysine and cholic acid, that can self-assemble under aqueous condition to form
stable micelles. The telodendrimer is prepared by Fmoc-chemistry with standard peptide synthesis
methods. Various hydrophobic drugs such as paclitaxel, etoposide, doxorubicin, SN-38, vinblastine,
vincristine, temsirolimus, and bortezomib can be easily incorporated into the nanoparticles with high
loading capacity. This nanoplatform is highly versatile. We can readily tune the particle size by varying
the configuration and composition of the telodendrimer. DiD near infra-red hydrophobic dye can be
used as drug surrogate for loading inside the nanoparticles for in vivo biodistribution studies in nude
mice bearing ovarian cancer xenograft. Particles smaller than 60 nm were found to preferentially
target the tumors, whereas particles at 150nm were found to concentrate at the liver and lung. The
surface chemistry of the nanoparticles can be easily modified by derivatizing the distal polyethylene
glycol tail of the telodendrimers with short oligopeptides comprised of D-lysine or D-aspartate.
Undesirable liver uptake was found to be very high for those nanoparticles with high surface charges,
either positive or negative. In contrast, liver uptake was very low but tumor uptake was very high
when the surface charge was slightly negative, e.g. one aspartate at the PEG terminus of each
telodendrimer. In the last few years, we have use one-bead one-compound combinatorial library
method to identify tumor targeting ligands. Ligation of one of these ligands OA02, that targets αvβ3
integrin, to the nanoparticle surface further improved tumor targeting and intracellular uptake at the
tumor site. In addition to xenograft models, we have also demonstrated that the nanoparticles could
preferentially target spontaneous mammary tumors of PyV-MT transgenic mice. We have just
completed a Phase I study of placiltaxel-loaded nanoparticles in companion dogs with lymphoma and
showed that the drug is safe. A Phase II study of the same preparation in companion dogs with solid
tumor is on-going.
As a part of our ongoing project on RNA therapeutics of mitochondrial disease, we have developed
methods to visualize fluorescent-tagged RNA in living cells and in live animals. The RNA is
prepared by incorporation of Alexa Fluor (AF)-or BODIPY-Texas Red (TR) tagged ribo UTP during in
vitro RNA directed transcription of DNA templates. The corresponding fluorophores can be
excited by 488 and 633 nm lasers respectively. RNA labeled with either fluorophore was taken up
by cultured cells in presence of a protein carrier. Live cell confocal microscopy of cells doubly
labeled with RNA and green (GFP) or red (RFP) fluorescent protein enabled the imaging of specific
steps of the intracellular transport process of the RNA in real time. In addition, we could visualize
its fate in mice after local or systemic administration of BODIPY-TR labeled RNA by live animal
imaging. These developments will facilitate the study of the transport and metabolism of
biologically active RNA in vitro and vivo.
Indo-US Workshop on “Applications of Molecular Imaging in Health, Disease and Drug Discovery” 19
Indo-US Science and Technology ForumIUSSTF
Imaging RNA in cells and in animals
Sukanta Jash, Biraj Mahato and Samit Adhya
Division of Molecular and Human Genetics, Indian Institute of Chemical Biology,
4 Raja S. C. Mullick Road, Calcutta 700032, India.
Indo-US Workshop on “Applications of Molecular Imaging in Health, Disease and Drug Discovery” 20
Indo-US Science and Technology ForumIUSSTF
Immunosuppression is a major obstacle to effective treatment of cancer, and can be a contributing
factor to therapy resistance. Several immunosuppressive cells have been identified, including
myeloid-derived suppressor cells (MDSC), and these have been shown to be increased in laboratory
models of cancer as well as cancer patients. MDSCs directly interfere with T cell mediated immunity,
and dendritic and natural killer cell function. Therefore significant effort is underway toward the
development of therapies that decrease MDSCs. The current study demonstrated that a previously
described deep tissue imaging modality, which utilized encapsulation of indocyanine green within a
calcium phosphosilicate-matrix nanoparticle ((ICG-CPSNP), can be utilized as an immunoregulatory
therapeutic agent. The theranostic application of ICG-CPSNPs as a photosensitizer for photodynamic
therapy (PDT) was shown to effectively block tumor growth in murine breast cancer models by
decreasing MDSCs while increasing immune effectors. As phosphorylated sphingolipid metabolites
have been shown to have immunomodulatory roles, it was hypothesized that the reduction of MDSCs
by ICG-CPSNP PDT was dependent upon bioactive sphingolipids. ICG-CPSNP PDT induced a
sphingosine kinase-dependent increase in dihydrosphingosine-1-phosphate (dhS1P). Indeed,
isolated MDSCs were decreased by treatment with dhS1P, but not sphingosine-1-phosphate, while
dhS1P induced a concomitant expansion of antitumor B cells. Adoptive transfer of these dhS1P-
induced B cells into tumor-bearing mice effectively blocked breast cancer tumor growth. Collectively,
these findings revealed that PDT utilizing the theranostic agent ICG-CPSNP, also behaved as a photo-
immunotherapy in breast cancer by prompting a decrease in immunosuppressive MDSCs and an
increase in immune effectors.
Conflict of Interest Disclaimer: Penn State Research Foundation has licensed calcium phosphosilicate
nanotechnology to Keystone Nano, Inc. (State College, PA). J.A. and M.K. are CSO and CMO of
Keystone Nano, respectively.
Nano"solutions" as Theranostics Dihydrosphingosine-1-Phosphate Triggers Expansion of Antitumor Immune Effectors
During Photoimmuno-Nanotherapy
Brian M. Barth, James M. Kaiser, Sriram S. Shanmugavelandy, Todd E. Fox, Erhan İ. Altinoğlu, Sarah A. Knupp. Georgina V. Bixler, Robert M. Brucklachen, Willard M. Freeman, Timothy M. Ritty, James
,H. Adair, and Mark Kester
The Pennsylvania State University College of Medicine, Hershey, PA 17033, USA
Indo-US Workshop on “Applications of Molecular Imaging in Health, Disease and Drug Discovery” 21
Indo-US Science and Technology ForumIUSSTF
The molecular imaging of tumor growth, angiogenesis and metastasis recently represent a major area
of research for the diagnosis and targeted therapy of many solid tumors in the area of cancer biology.
An
optimized set of high efficiency filters and spectral un-mixing algorithms allow taking full advantage of
bioluminescent and fluorescent reporters across the blue to near infrared wavelength region. In our
laboratory, we have recently developed many tumors in mice models and the effects of many drugs
have been tested and subsequently these tumors have been analyzed based on bioluminescence
technology. The analysis of some of these tumor images will be demonstrated during this workshop.
In vivo bioluminescent and fluorescent imaging allows the non-invasive detection and quantification
of orthotropic, metastatic and spontaneous tumors in the whole body of mouse. Many imaging
technology has been optimized for high sensitivity, such that micro metastases can be detected.
In Vivo Imaging of Tumors in Mice using Bioluminescence and Fluorescence Technologies
Gopal Kundu
Scientist-F, National Centre for Cell Science, Pune 411 007, India;
E-mail:[email protected]
Personalized treatment using stem, modified or genetically engineered, cells is becoming a reality in
the field of medicine, in which allogeneic or autologous cells can be used for treatment and possibly
for early diagnosis of diseases. Hematopoietic, stromal and organ specific stem cells are under
evaluation for cell-based therapies for cardiac, neurological, autoimmune and other disorders.
Cytotoxic or genetically altered T-cells are under clinical trial for the treatment of hematopoietic or
other malignant diseases. Before using stem cells in clinical trials, translational research in
experimental animal models are essential, with a critical emphasis on developing noninvasive
methods for tracking the temporal and spatial homing of these cells to target tissues. Moreover, it is
necessary to determine the transplanted cells, engraftment efficiency and functional capability.
Tracking of migration and homing of systemic or locally administered cells using MRI and other
complementary imaging modalities have passed the infancy. Now the technology is in a state where
robust experiments can be designed in translational studies utilizing cellular magnetic resonance
imaging (CMRI), nuclear medicine techniques and optical imaging. Tagging cells with reporter genes,
fluorescent dyes or different contrast agents transforms them into cellular probes or imaging agents.
In this presentation we will discuss the methods to transform cells into probes for in vivo imaging,
along with their advantages and disadvantages as well as the future clinical applicability of cellular
imaging method and corresponding imaging modality.
Points:1) Potential application of cells as diagnostic and therapeutic probes.2) In vitro making of potential therapeutic CTLs for malignant diseases3) Use of stem cells as gene carrier and delivery vehicles4) Use of multimodality approaches
In Vivo Cellular Imaging and its Role in Cell Therapy
Ali Arbab, MD, PhDAssociate Scientist
Cellular and Molecular Imaging Laboratory, Department of Radiology, Henry Ford Hospital, Detroit, MI, USA
&Associate Professor
Department of RadiologyWayne State University School of Medicine, Detroit, MI, USA
Indo-US Workshop on “Applications of Molecular Imaging in Health, Disease and Drug Discovery”
Indo-US Science and Technology ForumIUSSTF
22
Indo-US Workshop on “Applications of Molecular Imaging in Health, Disease and Drug Discovery” 23
Indo-US Science and Technology ForumIUSSTF
Glutamate and GABA are the major excitatory and inhibitory neurotransmitters in the matured 1mammalian central nervous system and together account for ~90% neurotransmitter pool in cortex .
These neurotransmitters play major roles in energy metabolism, cortical excitability, and cognitive 13function. It is well established that neuronal astrocytic substrate cycle exists in the brain. In vivo C
NMR studies have established that glutamatergic energetics is supported by oxidative glucose 1,2metabolism . Further, GABA contributes significantly to total neurotransmission and glucose
3oxidation by neurons in normal brain . These findings have led to specific predictions about the 4,5fundamental role of glucose in the support of neurotransmitter cycling . Dysfunction in glutamate
and GABA pathways are associated with many neurological and neuropsychiatric disorders. Thus,
glutamate, GABA and glutamine metabolism is of major importance to brain function and cerebral
well-being.
13In this presentation, I will discuss the strategy involving infusion of C labeled substrates 13together with C NMR spectroscopy to measure fluxes through glutamatergic and GABAergic
pathways. We are extending these measurements in mice to understand cerebral metabolism in
different cerebral disorders. I will be presenting our recent data for the investigation of flux through
glutamatergic and GABAergic pathways in healthy as well as in various abnormal/diseased conditions
such as neurodegeneration (Parkinson's, Alzheimer's), addiction (nicotine, alcohol).
References: 1. Sibson et al (1998) Proc Natl Acad Sci 95:316. 2. Patel et al (2004) J Cereb Blood Flow
Metab 24:972. 3. Patel et al (2005) Proc Natl Acad Sci 102:5588. 4. Magistratti et al (1998) Science
283:5801. (3) Hyder et al (2005) J Cereb Blod Flow Metab 26:865.
13 CNMR Investigations of Excitatory and Inhibitory Neurotransmission in Cerebral Disorders
Anant B. PatelNMR Microimaging & Spectroscopy,
Centre for Cellular and Molecular Biology, Uppal Road, Hyderabad, India
Indo-US Workshop on “Applications of Molecular Imaging in Health, Disease and Drug Discovery” 24
Indo-US Science and Technology ForumIUSSTF
Despite the great strides made in drug discoveries, many diseases have continued to take toll on
human lives and its quality. Recent advances in molecular biology and genomics have resulted into an
increasing number of novel biomarkers. These biomarkers can contribute extensively into the
development of translational medicine to diagnose diseases as well into the design of personalized
medicine to treat diseases. In the development of such drugs, molecular imaging can play a pivotal
role.
Cancer for example, thought to be initiated by genomic modulation at a cellular level, is known to
overexpress key proteins and RNAs of specific signaling pathways. These have become a hallmark of
many cancers, and an array of such biomarkers have been identified. Similarly the resolution of
common infection, in part, is associated with neutrophil apoptosis accelerated by reduction of
prosurvival factors such as lipopolysaccharides (LPS) and certain cytokines such as IL-1B. Apoptotic
neutrophils are presented in the outer layers, with Phosphatidylserine (PS), which is ordinarily
sequestered in the plasma membrane inner leaflet, and provides itself as an excellent target for
localizing infectious foci in vivo, and for monitoring the effectiveness of its treatment.
We hypothesize that targeting such biomarkers with specific fluorophores for optical imaging or with
radiolabeled specific biomolecules such as peptides on peptide nucleic acids for PET or SPECT imaging
of malignant lesions can help to address the challenges of drug discovery.
Examples of investigations from this laboratory will illustrate approaches not only for diagnosis of
diseases but also for their treatment, stratification and to determine the effectiveness of their
therapeutic interventions.
Supported by NIH CA 10923, BB 001809, ISIORR23709, PA ME-03-184, DOE/BER 63055, NIH CO27175,
NIH CA148565 and NuView, Inc.
Mathew L. Thakur, PhD
Department of Radiology, Thomas Jefferson University, Philadelphia, USA
ROLE OF MOLECULAR IMAGING IN DRUG DISCOVERY